Women’s imaging encompasses many radiology procedures related to women and the diseases that are most prevalent to women such as breast cancer or gynecological issues. Mammogram, breast ultrasound, breast MRI and breast biopsy are the most commonly used procedures.
Ivenia ABUS Premium was designed to help streamline the supplemental breast ultrasound workloads and enhance diagnoses by improving ease of use and image reproducibility.
There are no standards requiring radiologists to report on the presence of BACs, even though up to half of referring providers have indicated they would prefer to be made aware of the finding.
The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.
Research has once again shown that false-positive screening mammography results lead to increased anxiety for the women that receive them, and that these feelings can last for months. But how much should we fear the fear itself?
Human trials are still a few years off, but a new contrast agent for early-detection breast MRI has come through biomedical imaging investigations in mice with flying colors.
The DENSE Trial, the first randomized trial investigating the additional value of MRI for screening women with dense breasts, is featured in the current issue of Radiology.
A congresswoman with a personal breast cancer story joined imaging experts for a Capitol Hill briefing that served both to illuminate the importance of mammography screening and also condemn recent U.S. Preventive Services Task Force mammography guidelines.
Volpara Solutions today announced the release of VolparaDensity version 3.1 here at the Society of Breast Imaging’s SBI/ACR Breast Imaging Symposium in Orlando, Fla., April 25-28, 2015 (SBI Booth #214).
The cancer detection rate was significantly lower for breast MRI screenings than for diagnostic MRIs, according to a study published in the September issue of the Journal of the American College of Radiology.
Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.
The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.
